Volume 6, Number 6—December 2000
Perspective
Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya
Table 2
Site | Cure rate(s) observed (%) | Year(s) | Reference |
---|---|---|---|
Coast Province, Kenya | |||
Kajiwe, Kilifi district | 62-65 | 1994 | Olds et al., 45 |
Msambweni area, Kwale district | 65-96 | 1984-91 | present study |
Southern Kwale district | 84 | 1986 | King et al., 46 |
Kwale district | 87 | 1986 | Stephenson et al., 47 |
Elsewhere | |||
Senegal | 80-93 | 1995 | Shaw et al., 48 |
Ghana | 67 | 1994 | Chan et al., 9 |
Zimbabwe | 72 | 1986 | Taylor et al, 49 |
Mauritania | 90-95 | 1985-86 | Etard et al., 50 |
Ghana | 60 | 1984 | Mott et al., 42 |
Egypt | 59-62 | 1983 | el Malatawy et al., 51 |
Gambia | 57-93 | 1983 | Wilkins et al., 52 |
Tanzania | 66-83 | 1979 | McMahon and Kolstrup, 53 |
References
- World Health Organization. The control of schistosomiasis: second report of the WHO Expert Committee. Vol. 830 Geneva: 1993 WHO Technical Report.
- Hotez PJ, Zheng F, Long-qi X, Ming-gang C, Shu-hua X, Shu-xian L, Emerging and reemerging helminthiases and the public health of China. Emerg Infect Dis. 1997;3:303–10. DOIPubMedGoogle Scholar
- Praziquantel. USP Drug Information. Vol. I. Rockville (MD): United States Pharmacopeial Convention; 1998:2395-7.
- King CH, Mahmoud AA. Drugs five years later: praziquantel. Ann Intern Med. 1989;110:290–6.PubMedGoogle Scholar
- Davis A, Wegner DH. Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull World Health Organ. 1979;57:767–71.PubMedGoogle Scholar
- Brindley PJ. Drug resistance to schistosomicides and other anthelmintics of medical significance. Acta Trop. 1994;56:213–31. DOIPubMedGoogle Scholar
- Boisier P, Ramarokoto CE, Ravaoalimalala VE, Rabarijaona L, Serieye J, Roux J, Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. Trans R Soc Trop Med Hyg. 1998;92:451–3. DOIPubMedGoogle Scholar
- Chan MS, Nsowah-Nuamah NNN, Adjei S, Wen S, Hall A, Bundy DAP. Predicting impact of school-based treatment for urinary schistosomiasis given by the Ghana Partnership for Child Development. Trans R Soc Trop Med Hyg. 1998;92:386–9. DOIPubMedGoogle Scholar
- Jongsuksuntigul P, Imsomboon T. The impact of a decade long opisthorchiasis control program in northeastern Thailand. Southeast Asian J Trop Med Public Health. 1997;28:551–7.PubMedGoogle Scholar
- Schelling U, Frank W, Will R, Romig T, Lucius R. Chemotherapy with praziquantel has the potential to reduce the prevalence of Echinococcus multilocularis in wild foxes (Vulpes vulpes). Ann Trop Med Parasitol. 1997;91:179–86.PubMedGoogle Scholar
- Llayd S, Walters TM. Worming of dogs in mid-Wales for Echinococcus granulosus. Vet Rec. 1997;140:487–8.PubMedGoogle Scholar
- Olveda RM, Daniel BL, Ramirez BD, Aligui GD, Acosta LP, Fevidal P, Schistosomiasis japonica in the Philippines: the long-term impact of population-based chemotherapy on infection, transmission, and morbidity. J Infect Dis. 1996;174:163–72.PubMedGoogle Scholar
- Renganathan E, Cioli D. An international initiative on praziquantel use. Parasitol Today. 1998;14:390–1. DOIPubMedGoogle Scholar
- Kusel J, Hagan P. Praziquantel--its use, cost and possible development of resistance [news]. Parasitol Today. 1999;15:352–4. DOIPubMedGoogle Scholar
- Guisse F, Polman K, Stelma FF, Mbaye A, Talla I, Niang M, Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am J Trop Med Hyg. 1997;56:511–4.PubMedGoogle Scholar
- Stelma FF, Sall S, Daff B, Sow S, Niang M, Gryseels B. Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J Infect Dis. 1997;176:304–7. DOIPubMedGoogle Scholar
- Stelma FF, Talla I, Sow S, Kongs A, Niang M, Polman K, Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg. 1995;53:167–70.PubMedGoogle Scholar
- Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg. 1998;92:90–3. DOIPubMedGoogle Scholar
- Bennett JL, Day T, Feng-Tao L, Ismail M, Farghaly A. The development of resistance to anthelmintics: A perspective with an emphasis on the antischistosomal drug praziquantel. Exp Parasitol. 1997;87:260–7. DOIPubMedGoogle Scholar
- Fallon PG, Mubarak JS, Fookes RE, Niang M, Butterworth AE, Sturrock RF, Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates. Exp Parasitol. 1997;86:29–36. DOIPubMedGoogle Scholar
- Pereira C, Fallon PG, Cornette J, Capron A, Doenhoff MJ, Pierce RJ. Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni. Parasitology. 1998;117:63–73. DOIPubMedGoogle Scholar
- Cunha VM, Noel F. (Ca(2+)-Mg2+)ATPase in Schistosoma mansoni: evidence for heterogeneity and resistance to praziquantel. Mem Inst Oswaldo Cruz. 1998;93:181–2. DOIPubMedGoogle Scholar
- Cioli D, Pica Mattoccia L. Genetic analysis of hycanthone resistance in Schistosoma mansoni. Am J Trop Med Hyg. 1984;33:80–8.PubMedGoogle Scholar
- King CH, Lombardi G, Lombardi C, Greenblatt R, Hodder S, Kinyanjui H, Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection. Am J Trop Med Hyg. 1988;39:295–305.PubMedGoogle Scholar
- King CH, Muchiri EM, Ouma JH. Age-targeted chemotherapy for control of urinary schistosomiasis in endemic populations. Mem Inst Oswaldo Cruz. 1992;87:203–10. DOIPubMedGoogle Scholar
- Muchiri EM, Ouma JH, King CH. Dynamics and control of Schistosoma haematobium transmission in Kenya: an overview of the Msambweni Project. Am J Trop Med Hyg. 1996;55:127–34.PubMedGoogle Scholar
- Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology. New York: Oxford University Press; 1993.
- Anderson RM, May RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991. pp. 467-96; 507-20.
- Sturrock RF, Kinyanjui H, Thiongo FW, Tosha S, Ouma JH, King CH, Chemotherapy-based control of schistosomiasis haematobia. 3. Snail studies monitoring the effect of chemotherapy on transmission in the Msambweni area, Kenya. Trans R Soc Trop Med Hyg. 1990;84:257–61. DOIPubMedGoogle Scholar
- Muchiri EM. Association of water contact activities and risk of reinfection for S. haematobium after drug treatment in the Msambweni Area, Kenya [MS thesis, Epidemiology and Biostatistics]. Cleveland (OH): Case Western Reserve University; 1991.
- Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg. 1996;55:214–8.PubMedGoogle Scholar
- Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ. Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg. 1995;53:61–2.PubMedGoogle Scholar
- Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg. 1994;51:83–8.PubMedGoogle Scholar
- Laurent C, Lamothe F, Develoux M, Sellin B, Mouchet F. Ultrasonographic assessment of urinary tract lesions due to Schistosoma haematobium in Niger after four consecutive years of treatment with praziquantel. Trop Med Parasitol. 1990;41:139–42.PubMedGoogle Scholar
- Rainey BP, Moxon ER. Microbiology. When being hyper keeps you fit. Science. 2000;288:1186–7. DOIPubMedGoogle Scholar
- Field D, Magnasco MO, Moxon ER, Metzgar D, Tanaka MM, Wills C, Contingency loci, mutator alleles, and their interactions. Synergistic strategies for microbial evolution and adaptation in pathogenesis. Ann N Y Acad Sci. 1999;870:378–82. DOIPubMedGoogle Scholar
- Moxon ER, Rainey PB, Nowak MA, Lenski RE. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr Biol. 1994;4:24–33. DOIPubMedGoogle Scholar
- Caporale LH. Chance favors the prepared genome. Ann N Y Acad Sci. 1999;870:1–21. DOIPubMedGoogle Scholar
- Drake JW. The distribution of rates of spontaneous mutation over viruses, prokaryotes, and eukaryotes. Ann N Y Acad Sci. 1999;870:100–7. DOIPubMedGoogle Scholar
- Davis A, Biles JE, Ulrich AM. Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull World Health Organ. 1979;57:773–9.PubMedGoogle Scholar
- Mott KE, Dixon H, Osei-Tutu E, England EC, Davis A. Effect of praziquantel on hematuria and proteinuria in urinary schistosomiasis. Am J Trop Med Hyg. 1985;34:1119–26.PubMedGoogle Scholar
- Stephenson LS, Latham MC, Kinoti SN, Oduori ML. Sensitivity and specificity of reagent strips in screening of Kenyan children for Schistosoma haematobium infection. Am J Trop Med Hyg. 1984;33:862–71.PubMedGoogle Scholar
- Pugh RN, Bell DR, Gilles HM. Malumfashi Endemic Diseases Research Project, XV. The potential medical importance of bilharzia in northern Nigeria: a suggested rapid, cheap and effective solution for control of Schistosoma haematobium infection. Ann Trop Med Parasitol. 1980;74:597–613.PubMedGoogle Scholar
- Olds GR, King CH, Hewlett J, Olveda R, Wu G, Ouma JH, Double-blind placebo controlled study of concurrent administration of albendazole and praziquantel in school children with schistosomiasis and geohelminths. J Infect Dis. 1999;179:996–1003. DOIPubMedGoogle Scholar
- King CH, Wiper DWD, De Stigter KV, Peters PA, Koech D, Ouma JH, . Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya. Am J Trop Med Hyg. 1989;40:507–13.PubMedGoogle Scholar
- Stephenson LS, Latham MC, Kurz KM, Kinoti SN. Single dose metrifonate or praziquantel treatment in Kenyan children. II. Effects on growth in relation to Schistosoma haematobium and hookworm egg counts. Am J Trop Med Hyg. 1989;41:445–53.PubMedGoogle Scholar
- Shaw DJ, Vercruysse J, Picquet M, Sambou B, Ly A. The effect of different treatment regimens on the epidemiology of seasonally transmitted Schistosoma haematobium infections in four villages in the Senegal River Basin, Senegal. Trans R Soc Trop Med Hyg. 1999;93:142–50. DOIPubMedGoogle Scholar
- Taylor P, Murare HM, Manomano K. Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium. J Trop Med Hyg. 1988;91:13–7.PubMedGoogle Scholar
- Etard JF, Borel E, Segala C. Schistosoma haematobium infection in Mauritania: two years of follow-up after a targeted chemotherapy--a life-table approach of the risk of reinfection. Parasitology. 1990;100:399–406. DOIPubMedGoogle Scholar
- el Malatawy A, el Habashy A, Lechine N, Dixon H, Davis A, Mott KE. Selective population chemotherapy among schoolchildren in Beheira governorate: the UNICEF/Arab Republic of Egypt/WHO Schistosomiasis Control Project. Bull World Health Organ. 1992;70:47–56.PubMedGoogle Scholar
- Wilkins HA, Blumenthal UJ, Hayes RJ, Tulloch S. Resistance to reinfection after treatment of urinary schistosomiasis. Trans R Soc Trop Med. 1987;81:29–35. DOIPubMedGoogle Scholar
- McMahon JE, Kolstrup N. Praziquantel: a new schistosomicide against Schistosoma haematobium. BMJ. 1979;2:1396–8. DOIPubMedGoogle Scholar
Page created: December 17, 2010
Page updated: December 17, 2010
Page reviewed: December 17, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.